Modulation of factor 11 expression
View Patent ↗Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
1. A method of treating a thromboembolic complication in an animal, comprising administering to an animal in need thereof a compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified oligonucleotide is at least 90% complementary to a Factor 11 nucleic acid.
2. The method of claim 1 , wherein the administering prolongs aPTT in the animal.
3. The method of claim 1 , wherein the administering reduces platelet quantity as measured by platelet factor-4 quantification in the animal.
4. The method of claim 1 , wherein the administering reduces amount of bleeding in response to injury in the animal.
5. The method of claim 1 , wherein the administering prevents thrombus formation in the animal.
6. The method of claim 1 , wherein the thromboembolic complication is any of the group consisting of deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.
7. The method of claim 1 , wherein the compound is for coadministation with any of the group consisting of aspirin, clopidogrel, dipyridamole, heparin, lepirudin, ticlopidine, warfarin, apixaban, rivaroxaban, LOVENOX, and Factor Xa inhibitor.
8. The method of claim 1 , wherein the compound is for concomitant administration with any of the group consisting of aspirin, clopidogrel, dipyridamole, heparin, lepirudin, ticlopidine, warfarin, apixaban, rivaroxaban, LOVENOX, and Factor Xa inhibitor.
9. A method of reducing expression of Factor 11, comprising contacting a cell or tissue with a compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 12 contiguous nucleobases of SEQ ID NO: 217 or 223, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1 as measured over the entirety of the modified oligonucleotide.
10. The method of claim 9 , wherein the compound consists of a single-stranded modified oligonucleotide.
11. The method of claim 10 , wherein at least one internucleoside linkage of said compound is a modified internucleoside linkage.
12. The method of claim 11 , wherein each internucleoside linkage of said compound is a phosphorothioate internucleoside linkage.
13. The method of claim 10 , wherein at least one nucleoside of said compound comprises a modified sugar.
14. The method of claim 13 , wherein at least one modified sugar of said compound is a bicyclic sugar.
15. The method of claim 14 , wherein each of the at least one bicyclic sugar comprises a 4′-(CH 2 ) n —O-2′ bridge, wherein n is 1 or 2.
16. The method of claim 14 , wherein each of the at least one bicyclic sugar comprises a 4′-CH(CH 3 )—O-2′ bridge.
17. The method of claim 13 , wherein at least one modified sugar of said compound comprises a 2′-O-methoxyethyl group.
18. The method of claim 10 , wherein said compound comprises at least one tetrahydropyran modified nucleoside wherein a tetrahydropyran ring replaces the furanose ring.
19. The method of claim 18 , wherein each of the at least one tetrahydropyran modified nucleoside has the structure:
wherein Bx is an optionally protected heterocyclic base moiety.
20. The method of claim 10 , wherein at least one nucleoside of said compound comprises a modified nucleobase.
21. The method of claim 20 , wherein the modified nucleobase is a 5-methylcytosine.
22. The method of claim 10 , wherein the modified oligonucleotide comprises:
a gap segment consisting of linked deoxynucleosides;
a 5′ wing segment consisting of linked nucleosides;
a 3′ wing segment consisting of linked nucleosides;
wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment, and wherein each nucleoside of each wing segment comprises a modified sugar.
23. The method of claim 22 , wherein the modified oligonucleotide consists of 20 linked nucleosides.
24. The method of claim 23 , wherein the modified oligonucleotide comprises:
a gap segment consisting of ten linked deoxynucleosides;
a 5′ wing segment consisting of five linked nucleosides;
a 3′ wing segment consisting of five linked nucleosides;
wherein the gap segment is positioned immediately adjacent and between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5-methylcytosine.
25. The method of claim 22 , wherein the nucleobase sequence of the modified oligonucleotide comprises the sequence of SEQ ID NO: 217 or 223.
26. The method of claim 24 , wherein the nucleobase sequence of the modified oligonucleotide consists of the sequence of SEQ ID NO: 217 or 223.
27. The method of claim 10 , wherein the nucleobase sequence of the modified oligonucleotide comprises the sequence of SEQ ID NO: 217 or 223.
28. The method of claim 10 , wherein the nucleobase sequence of the modified oligonucleotide consists of the sequence of SEQ ID NO: 217 or 223.
29. The method of claim 24 , wherein the nucleobase sequence of the modified oligonucleotide consists of the sequence of SEQ ID NO: 217.
30. The method of claim 24 , wherein the nucleobase sequence of the modified oligonucleotide consists of the sequence of SEQ ID NO: 223.